Medicine
Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors
Silvia Novello
SILVIA NOVELLO, University of Turin
Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello when she presented data on a range of drugs which target angiogenesis by inhibiting more than one tyrosine kinase pathway. She talked about the evidence so far with Peter Goodwin.
Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello when she presented data on a range of drugs which target angiogenesis by inhibiting more than one tyrosine kinase pathway. She talked about the evidence so far with Peter Goodwin.
Similar Interviews
Bivalirudin For Angioplasty: Expensive Heparin?»
Tony Gershlick, University of Leicester
Adnan Kastrati, Deutsches Herzzentrum, Munich
Using bivalirudin instead of heparin during angioplasty wasn't any better for preventing death, MI or urgent revascularisation in the 4,500-patient ISAR-REACT 3 study presented at the ACC annual meeting. Tony Gershlick and Adnan Kastrati discuss the study with Peter Goodwin and Sarah Freeman.Tony Gershlick, University of Leicester
Adnan Kastrati, Deutsches Herzzentrum, Munich
Tropical Health Research: London Scientist Honored»
Brian Greenwood, London School of Hygiene and Tropical Medicine
Brian Greenwood, of the London School of Hygiene and Tropical Medicine, has won the Hideyo Noguchi Africa Prize for his numerous achievements in tropical disease research. He talked withy Derek Thorne about his work, including the pivotal research proving that bed nets can help prevent malaria.Brian Greenwood, London School of Hygiene and Tropical Medicine
© 2008 Audio Medica - Medical Audio News Interviews & Podcasts. 
Post a comment